NO20031185L - Fusjonsprotein fra antistoff-cytokin-cytokininhibitor (selektokin) for anvendelse som mål-pesifikt prolegemiddel - Google Patents

Fusjonsprotein fra antistoff-cytokin-cytokininhibitor (selektokin) for anvendelse som mål-pesifikt prolegemiddel

Info

Publication number
NO20031185L
NO20031185L NO20031185A NO20031185A NO20031185L NO 20031185 L NO20031185 L NO 20031185L NO 20031185 A NO20031185 A NO 20031185A NO 20031185 A NO20031185 A NO 20031185A NO 20031185 L NO20031185 L NO 20031185L
Authority
NO
Norway
Prior art keywords
cytokine
selectokine
antibody
target
fusion protein
Prior art date
Application number
NO20031185A
Other languages
English (en)
Other versions
NO20031185D0 (no
Inventor
Thomas Wuerst
Dieter Moosmayer
Matthias Grell
Peter Scheurich
Original Assignee
Pfizenmaier Klaus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizenmaier Klaus filed Critical Pfizenmaier Klaus
Publication of NO20031185D0 publication Critical patent/NO20031185D0/no
Publication of NO20031185L publication Critical patent/NO20031185L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20031185A 2000-09-15 2003-03-14 Fusjonsprotein fra antistoff-cytokin-cytokininhibitor (selektokin) for anvendelse som mål-pesifikt prolegemiddel NO20031185L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10045592A DE10045592A1 (de) 2000-09-15 2000-09-15 Ein Antikörper-TNF-TNF Inhibitor Fusionsprotein (TNF-Selektokin) als zielspezifisches Prozytokin zur Tumortherapie
PCT/EP2001/010730 WO2002022833A1 (de) 2000-09-15 2001-09-17 Fusionsprotein aus antikörper-zytokin-zytokin inhibitor (selektokin) als zielspezifisches prodrug

Publications (2)

Publication Number Publication Date
NO20031185D0 NO20031185D0 (no) 2003-03-14
NO20031185L true NO20031185L (no) 2003-05-05

Family

ID=7656260

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20031185A NO20031185L (no) 2000-09-15 2003-03-14 Fusjonsprotein fra antistoff-cytokin-cytokininhibitor (selektokin) for anvendelse som mål-pesifikt prolegemiddel

Country Status (22)

Country Link
US (1) US20040053829A1 (no)
EP (1) EP1317556A1 (no)
JP (1) JP2004508828A (no)
KR (1) KR20030048041A (no)
CN (1) CN1214115C (no)
AU (1) AU2001293819A1 (no)
BG (1) BG107613A (no)
BR (1) BR0113928A (no)
CA (1) CA2422759A1 (no)
DE (1) DE10045592A1 (no)
EE (1) EE200300100A (no)
HR (1) HRP20030192A2 (no)
HU (1) HUP0301693A3 (no)
IL (1) IL154185A0 (no)
MX (1) MXPA03002229A (no)
NO (1) NO20031185L (no)
PL (1) PL360540A1 (no)
RU (1) RU2003106429A (no)
SK (1) SK2812003A3 (no)
WO (1) WO2002022833A1 (no)
YU (1) YU18903A (no)
ZA (1) ZA200302008B (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7468354B2 (en) 2000-12-01 2008-12-23 Genspera, Inc. Tissue specific prodrugs
PE20021080A1 (es) * 2001-04-12 2003-02-12 Boehringer Ingelheim Int Un anticuerpo especifico fapo bibh1 en el tratamiento del cancer
DE10144252A1 (de) * 2001-08-31 2003-03-27 Fraunhofer Ges Forschung Nanopartikel mit daran immobilisiertem biologisch aktivem TNF
US7057026B2 (en) 2001-12-04 2006-06-06 Solexa Limited Labelled nucleotides
DE10247755B4 (de) * 2002-10-14 2006-01-19 Pfizenmaier, Klaus, Prof. Dr. Selektive, lokale Aktivierung von Mitgliedern der TNF-Rezeptorfamilie durch systemisch inaktive nicht-Antikörper-TNF-Liganden-Fusionsproteine
AU2004210088A1 (en) * 2003-02-06 2004-08-19 Micromet Ag Trimeric polypeptide construct to induce an enduring T cell response
US7374898B2 (en) * 2004-10-12 2008-05-20 The Research Foundation Of State University Of New York Peptide inhibitors against seprase
WO2006117910A1 (ja) 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. 抗血小板膜糖蛋白質ⅵモノクローナル抗体
EP1736482A1 (en) * 2005-06-20 2006-12-27 INSERM (Institut National de la Santé et de la Recherche Medicale) Recombinant trimeric 4-1BBL
DE102005036542A1 (de) * 2005-08-03 2007-02-08 Universität Stuttgart CTL-Prodrug
EP1972350A1 (en) * 2007-03-20 2008-09-24 Rijksuniversiteit Groningen Dual targeting system
EP2009022A1 (en) * 2007-06-26 2008-12-31 Apogenix GmbH Trimeric death ligands with enhanced activity (tenascin)
US20090304719A1 (en) 2007-08-22 2009-12-10 Patrick Daugherty Activatable binding polypeptides and methods of identification and use thereof
US8895702B2 (en) 2008-12-08 2014-11-25 City Of Hope Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies
WO2010081173A2 (en) * 2009-01-12 2010-07-15 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
US8399219B2 (en) 2009-02-23 2013-03-19 Cytomx Therapeutics, Inc. Protease activatable interferon alpha proprotein
CA3115461A1 (en) * 2018-03-09 2019-09-12 AskGene Pharma, Inc. Novel cytokine prodrugs
CN113840832A (zh) 2018-05-14 2021-12-24 狼人治疗公司 可活化白介素-2多肽及其使用方法
US20210130430A1 (en) 2018-05-14 2021-05-06 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
WO2019222294A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
CN112534052B (zh) * 2018-07-25 2024-09-20 奥美药业有限公司 全新il-21前药及使用方法
MX2021003543A (es) * 2018-09-27 2021-06-23 Xilio Dev Inc Polipeptidos de citocinas enmascaradas.
KR20220023988A (ko) 2019-05-14 2022-03-03 웨어울프 세라퓨틱스, 인크. 분리 모이어티 및 이의 사용 방법
WO2020252264A1 (en) 2019-06-12 2020-12-17 AskGene Pharma, Inc. Novel il-15 prodrugs and methods of use thereof
WO2021035188A1 (en) * 2019-08-21 2021-02-25 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
AU2020353235A1 (en) * 2019-09-28 2022-03-31 AskGene Pharma, Inc. Cytokine prodrugs and dual-prodrugs
BR112022009110A2 (pt) 2019-11-14 2022-07-26 Werewolf Therapeutics Inc Polipeptídeos de citocina ativáveis e métodos de uso destes
JP7767290B2 (ja) 2020-01-11 2025-11-11 アスクジーン・ファーマ・インコーポレイテッド 新規なマスクされたサイトカインおよびその使用方法
JP2023553323A (ja) 2020-11-25 2023-12-21 エクシリオ デベロップメント, インコーポレイテッド 腫瘍特異的に切断可能なリンカー

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981001145A1 (en) * 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US5502037A (en) * 1993-07-09 1996-03-26 Neuromed Technologies, Inc. Pro-cytotoxic drug conjugates for anticancer therapy
US5763733A (en) * 1994-10-13 1998-06-09 Enzon, Inc. Antigen-binding fusion proteins
US5614191A (en) * 1995-03-15 1997-03-25 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
DE19900709A1 (de) * 1999-01-11 2000-07-13 Falkenberg Frank W Eine neue Applikationsform für biologisch wirksame Substanzen zur Anwendung bei Menschen und Tieren

Also Published As

Publication number Publication date
RU2003106429A (ru) 2004-08-27
PL360540A1 (en) 2004-09-06
ZA200302008B (en) 2004-06-25
DE10045592A1 (de) 2002-03-28
KR20030048041A (ko) 2003-06-18
CN1214115C (zh) 2005-08-10
NO20031185D0 (no) 2003-03-14
SK2812003A3 (en) 2003-11-04
CA2422759A1 (en) 2003-03-17
IL154185A0 (en) 2003-07-31
HRP20030192A2 (en) 2005-10-31
HUP0301693A2 (hu) 2003-08-28
EP1317556A1 (de) 2003-06-11
CN1458977A (zh) 2003-11-26
BR0113928A (pt) 2003-07-22
US20040053829A1 (en) 2004-03-18
YU18903A (sh) 2006-05-25
WO2002022833A1 (de) 2002-03-21
AU2001293819A1 (en) 2002-03-26
EE200300100A (et) 2005-02-15
MXPA03002229A (es) 2005-06-20
JP2004508828A (ja) 2004-03-25
HUP0301693A3 (en) 2005-11-28
BG107613A (bg) 2003-12-31

Similar Documents

Publication Publication Date Title
NO20031185D0 (no) Fusjonsprotein fra antistoff-cytokin-cytokininhibitor (selektokin) for anvendelse som målspesifikt prolegemiddel
NO20030055L (no) Colchinolderivater som angiogenese inhibitorer
NO20023828L (no) Pyrimidin-4-on derivater som LDL-PLA2 inhibitorer
DK2253620T3 (da) Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer
DK1244647T3 (da) Quinzolinderivater som VIGF-inhibitorer
DE60136416D1 (de) Kraftverstärkender Mechanismus für Hefter
DK1286989T3 (da) Prodrug fra en ICE
DE60106252D1 (de) Substituierte pyprolopyridinonderivate als phosphodiesterase-inhibitoren
DE60115817D1 (de) Nickel-Basis-Hartlotlegierung
NO20024997D0 (no) 2-guanidino-4-arylkinazoliner som NHE-3-inhibitorer
ATE298332T1 (de) Decahydro-isochinolinderivate
NO20032613L (no) Farmasöytisk sammensetning som har forbedret vannlöselighet
DE60129982D1 (de) Schweisshemmende zusammensetzungen
DE60116311D1 (de) Schweisshemmende zusammensetzungen
NO20016201D0 (no) Tienopyrimidiner som fosfodiesteraseinhibitorer
DK1571140T3 (da) Substituerede C-cyjklohexylmethylamin-derivater
DE60017273D1 (de) Laserschweisssystem
DK1442026T3 (da) Triazolderivater som cyclooxygenase (COX)-inhibitorer
NO20032075D0 (no) Rammer for riggtang
DK1322592T4 (da) Substituerede 1-aminobutan-3-ol-derivater
DE60124282D1 (de) Leitweglenkung von kurznachrichten
DE50102987D1 (de) Gelenkhalterung
DE60129224D1 (de) Tetrazolderivate
ATE280752T1 (de) Aminomethyl-phenyl-cyclohexanonderivate
FR2818814B1 (fr) Source laser